Statins as a new therapeutic perspective in myocarditis and postmyocarditis dilated cardiomyopathy: Editorial to "pitavastatin regulates helper T-cell differentiation and ameliorates autoimmune myocarditis in mice" by K. Tajiri et al.

Cardiovascular Drugs and Therapy

Volumn 27, Issue 5, 2013, Pages 365-369

  Lazzerini, Pietro Enea ^a   Capecchi, Pier Leopoldo ^a   Laghi Pasini, Franco ^a  

^a UNIVERSITY OF SIENA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 17; INTERLEUKIN 23; INTERLEUKIN 6; PITAVASTATIN; ROSUVASTATIN; SIMVASTATIN; T LYMPHOCYTE RECEPTOR;

ADENOVIRUS; ANTIGEN PRESENTING CELL; AUTOIMMUNITY; CD4+ T LYMPHOCYTE; CONGESTIVE CARDIOMYOPATHY; COXSACKIE VIRUS B; CYTOKINE PRODUCTION; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; HELPER CELL; HISTOPATHOLOGY; HUMAN; HUMAN HERPESVIRUS 6; HUMAN PARVOVIRUS B19; MOUSE; MYOCARDITIS; NONHUMAN; PATHOGENESIS; POSTMYOCARDITIS DILATED CARDIOMYOPATHY; PRIORITY JOURNAL; RAT; REVIEW; TH17 CELL;

ANIMALS; AUTOIMMUNE DISEASES; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MYOCARDITIS; QUINOLINES;

EID: 84885186836     PISSN: 09203206     EISSN: 15737241     Source Type: Journal    
DOI: 10.1007/s10557-013-6475-8     Document Type: Review

References (29)

1. Kindermann I, Barth C, Mahfoud F, et al. Update on myocarditis. J Am Coll Cardiol. 2012;59:779-92.
2. Corsten MF, Schroen B, Heymans S. Inflammation in viral myocarditis: friend or foe? Trends Mol Med. 2012;18:426-37.
3. Fabre A, Sheppard MN. Sudden adult death syndrome and other non-ischaemic causes of sudden cardiac death. Heart. 2006;92:316-20.
4. Barin JG, Ciháková D. Control of inflammatory heart disease by CD4(+) T cells. Ann N Y Acad Sci. 2013;1285:80-96.
5. Baldeviano GC, Barin JG, Talor MV, et al. Interleukin-17A is dispensable for myocarditis but essential for the progression to dilated cardiomyopathy. Circ Res. 2010;106:1646-55.
6. Nindl V, Maier R, Ratering D, et al. Cooperation of Th1 and Th17 cells determines transition from autoimmune myocarditis to dilated cardiomyopathy. Eur J Immunol. 2012;42:2311-21.
7. Wierzbicki AS, Poston R, Ferro A. The lipid and non-lipid effects of statins. Pharmacol Ther. 2003;99:95-112.
8. Bhatnagar D, Soran H, Durrington PN. Hypercholesterolaemia and its management. BMJ. 2008;337:a993.
9. Corsini A, Bellosta S, Baetta R, Fumagalli R, Paoletti R, Bernini F. New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol Ther. 1999;84:413-28.
10. Lazzerini PE, Capecchi PL, Selvi E, et al. Statins and the joint: multiple targets for a global protection? Semin Arthritis Rheum. 2011;40:430-46.
11. Willey JZ, Elkind MS. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in the treatment of central nervous system diseases. Arch Neurol. 2010;67:1062-7.
12. Ghittoni R, Patrussi L, Pirozzi K, et al. Simvastatin inhibits T-cell activation by selectively impairing the function of Ras superfamily GTPases. FASEB J. 2005;19:605-7.
13. Ghittoni R, Napolitani G, Benati D, et al. Simvastatin inhibits the MHC class II pathway of antigen presentation by impairing Ras superfamily GTPases. Eur J Immunol. 2006;36:2885-93.
14. Ghittoni R, Lazzerini PE, Laghi-Pasini F, Baldari CT. T lymphocytes as targets of statins: molecular mechanisms and therapeutic perspectives. Inflamm Allergy Drug Targets. 2007;6:3-16.
15. Zhang X, Markovic-Plese S. Statins' immunomodulatory potential against Th17 cell-mediated autoimmune response. Immunol Res. 2008;41:165-74.
16. Azuma RW, Suzuki J, Ogawa M, et al. HMG-CoA reductase inhibitor attenuates experimental autoimmune myocarditis through inhibition of T cell activation. Cardiovasc Res. 2004;64:412-20.
17. Liu W, Li WM, Gao C, Sun NL. Effects of atorvastatin on the Th1/Th2 polarization of ongoing experimental autoimmune myocarditis in Lewis rats. J Autoimmun. 2005;25:258-63.
18. Li WM, Liu W, Gao C, Zhou BG. Immunoregulatory effects of atorvastatin on experimental autoimmune myocarditis in Lewis rats. Immunol Cell Biol. 2006;84:274-80.
19. Tang Q, Huang J, Qian H, et al. Antiarrhythmic effect of atorvastatin on autoimmune myocarditis is mediated by improving myocardial repolarization. Life Sci. 2007;80:601-8.
20. Wu JL, Matsui S, Zong ZP, et al. Amelioration of myocarditis by statin through inhibiting cross-talk between antigen presenting cells and lymphocytes in rats. J Mol Cell Cardiol. 2008;44:1023-31.
21. Zhang A, Zhang H, Wu S. Immunomodulation by atorvastatin upregulates expression of gap junction proteins in coxsackievirus B3 (CVB3)-induced myocarditis. Inflamm Res. 2010;59:255-62.
22. Guan J, Sun X, Liang Y, et al. Atorvastatin attenuates Coxsackie virus B3m-induced viral myocarditis in mice. J Cardiovasc Pharmacol. 2010;56:540-7.
23. Liu X, Li B, Wang W, et al. Effects of HMG-CoA reductase inhibitor on experimental autoimmune myocarditis. Cardiovasc Drugs Ther. 2012;26:121-30.
24. Tajiri K, Shimojo N, Sakai S, et al. Pitavastatin regulates helper T-cell differentiation and ameliorates autoimmune myocarditis in mice. Cardiovasc Drugs Ther. 2013;27:this issue
25. Cortez DM, Feldman MD, Mummidi S, et al. IL-17 stimulates MMP-1 expression in primary human cardiac fibroblasts via p38 MAPK- and ERK1/2-dependent C/EBP-beta, NF-kappaB, and AP-1 activation. Am J Physiol Heart Circ Physiol. 2007;293:H3356-65.
26. Valente AJ, Yoshida T, Gardner JD, Somanna N, Delafontaine P, Chandrasekar B. Interleukin-17A stimulates cardiac fibroblast proliferation and migration via negative regulation of the dual-specificity phosphatase MKP-1/DUSP-1. Cell Signal. 2012;24:560-8.
27. Liu Y, Zhu H, Su Z, et al. IL-17 contributes to cardiac fibrosis following experimental autoimmune myocarditis by a PKCβ/Erk1/2/NF-κB- dependent signaling pathway. Int Immunol. 2012;24:605-12.
28. Bielecka-Dabrowa A, Mikhailidis DP, Hannam S, Aronow WS, Rysz J, Banach M. Statins and dilated cardiomyopathy: do we have enough data? Expert Opin Investig Drugs. 2011;20:315-23.
29. Wojnicz R, Wilczek K, Nowalany-Kozielska E, et al. Usefulness of atorvastatin in patients with heart failure due to inflammatory dilated cardiomyopathy and elevated cholesterol levels. Am J Cardiol. 2006;97:899-904.